Mark your calendar, Java making a strong entrance to 2025 China International Bicycle Fair
Under the theme "Ride Different.", JAVA will present several cutting-edge models that embody the brand's latest advancements in aerodynamics, lightweight carbon technology, and urban mobility design.
JAVA's official 2025 New Product Launch will be held on-site on May 5, offering attendees a first-hand look at our latest models, along with exclusive technical insights. A number of influential KOLs and media representatives from across China will be attending the event — we welcome all cycling enthusiasts and partners to join us!
VITTORIA ｜Flagship Carbon Road Bike
Featuring a race-optimized full carbon frame and integrated cockpit system, VITTORIA is built for both aerodynamic speed and long-distance comfort. It represents JAVA's most advanced road platform to date.
New TT Bike ｜Born for Speed and Precision
Engineered for triathlons and time trials, the new TT model integrates aero frame geometry with deep-section wheels, offering elite-level speed stability and reduced drag.
CIMA ｜All-New Carbon Fiber Mountain Bike
The CIMA is JAVA's next-gen MTB built with a lightweight carbon fiber frame, front hydraulic lock-out suspension, and sharp geometry for maximum control on aggressive terrain.
SABBIA-MINI ｜Compact Gravel for Urban & Trail Exploration
A standout model at this year's show, the SABBIA-MINI blends light gravel capabilities with a space-saving frame design, making it perfect for multi-scenario riding—from city streets to light trails. Its geometry is specially tailored for smaller riders and younger cyclists, offering a comfortable and confident ride for teens or entry-level users.
CL & CL-CB ｜Urban Mini Bikes with Attitude
JAVA's 20-inch small-wheel urban bikes offer style and function. The CL emphasizes agility for city commutes, while the CL-CB adds vintage flair for the trend-conscious rider.
Cycling Gear & Apparel ｜New in 2025
JAVA is also launching a new line of cycling wear and accessories, including high-performance jerseys, padded gloves, aero helmets, and more, designed to complement our bikes and support every rider's needs.
JAVA's Marketing Director stated:
"2025 is a transformative year for JAVA. We're proud to unveil a comprehensive lineup that represents our commitment to innovation, design, and rider-first performance. We look forward to connecting with the global cycling community at China Cycle."
Throughout the event, JAVA will also host product showcases, interactive giveaways, and technical sessions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
20 minutes ago
- Korea Herald
DIFC's H1 2025 results fuel Dubai's economic vision (D33) and demonstrate global leadership in financial services and innovation
DUBAI, UAE, July 28, 2025 /PRNewswire/ -- Dubai International Financial Centre (DIFC), the leading global financial centre in the Middle East, Africa and South Asia (MEASA), announced its best-ever performance for the first half of a year, reinforcing its contribution in driving the future of finance and the Dubai Economic Agenda (D33). DIFC saw a record 1,081 new active registered companies join the Centre during the first six months of 2025 bringing the total number of active registered companies to 7,700. 47,901 professionals now work in DIFC. Total Financial services authorisations grew 28 per cent year-on-year - 78 in H1 2025 compared to 61 in H1 2024. DIFC's banking and capital markets cluster consists of 289 companies, up from 247 a year ago. The number of firms in the wealth and asset management sector increased to 440, up from 370 in H1 2024, growing 19 per cent year-on-year, with 85 hedge funds, including 69 billion-dollar funds. Over 10,000 funds are being managed or marketed from DIFC. Additionally, 1,035 entities associated with family businesses now operate from the Centre, up from 600 a year ago. The number of foundations in DIFC have accelerated to 842, up from 548 in H1 2024. 135 insurance-related firms operate from DIFC. Gross Written Premiums advanced to USD 3.5bn for 2024, compared to USD 2.6bn a year earlier. The number of FinTech and Innovation companies reached 1,388, up from 1,081 in H1 2024 a surge of 28 per cent. Total active non-financial entities increased to 6,335, up from 4,935 a year earlier. H.E. Essa Kazim, Governor of DIFC said: "DIFC remains the driving force behind Dubai's economic growth, as a key enabler of the financial services sector's expansion and diversification. Our consistent performance across all sectors and rising global standing strengthen our commitment to supporting innovation, attracting global capital, and reinforcing Dubai's status as one of the world's most competitive and diversified economies." Dubai is one of eight cities globally to possess 'broad and deep' capabilities across all parts of the finance industry in the Global Financial Centres Index, alongside London, New York, and Paris. Over 1.6mn sq. ft. of commercial space is currently under development and construction being accelerated to meet demand. The new space will be ready for occupancy starting from Q1 2026.
Korea Herald
an hour ago
- Korea Herald
FNZ Announces Strategic Partnership with Microsoft to Accelerate the Transformation of the Wealth Management Industry
LONDON, July 28, 2025 /PRNewswire/ -- FNZ, a leading end-to-end wealth management platform has today announced a global, five-year strategic partnership with Microsoft to transform the wealth management industry through technology, innovation and AI-driven digital solutions. The partnership combines FNZ's industry-leading technology, wealth management expertise and global reach with Microsoft's advanced AI capabilities, cloud infrastructure and engineering excellence. By integrating Microsoft Azure AI Foundry at the heart of its platform, FNZ is redefining how financial institutions, advisors and their clients interact by delivering more personalized, intelligent and resilient digital wealth management experiences. This collaboration with Microsoft accelerates this transformation by helping FNZ bring new solutions to market faster, enhance client outcomes, boost advisor productivity and drive innovation across industry. With more than 650 financial institution partners, over 26 million end investors and close to $2 trillion in assets under administration, FNZ brings scale to the partnership. This provides access to one of the largest wealth management data sets in the world, enabling the powerful application of AI, cloud technologies and analytics to deliver deeper insights, greater personalization and better outcomes for advisors, clients and institutions alike. Partnership Highlights Through the partnership, FNZ will work with Microsoft to deliver advanced AI tools, drive new technology development and collaborate on joint go-to-market initiatives, including: Roman Regelman, Group President, FNZ, said:"FNZ has always been at the forefront of innovation in wealth-management technology. Partnering with Microsoft allows us to accelerate our AI-led roadmap and enhances our ability to deliver personalized, intelligent and resilient solutions to our clients, strengthening our position of leadership." "Together, we are not just upgrading technology. We are setting a new standard for how wealth management is delivered. Partnering with Microsoft further advances our mission to open up wealth, by making investing more accessible to more people worldwide." Bill Borden, Corporate Vice President, Worldwide Financial Services, Microsoft, said:"Our partnership brings together Microsoft's AI and cloud technologies with FNZ's global platform and expertise in wealth management to deliver insights that will lead to more impactful and personalized experiences for advisors and their clients. Together, we're helping financial institutions lead as Frontier Firms by reimagining their operations through agentic AI, accelerating innovation, and unlocking new value across the wealth management ecosystem." FNZ is backed by some of the world's largest institutional shareholders, including Caisse de dépôt et placement du Québec (La Caisse), Canada Pension Plan Investment Board (CPP Investments), Generation Investment Management and Motive Partners.
Korea Herald
4 hours ago
- Korea Herald
Antengene Announces XPOVIO® Approved in China for the Second-Line Treatment of Multiple Myeloma, Marking the Third Approved Indication of the Drug
SHANGHAI and HONG KONG, July 28, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic malignancies and solid tumors, today announced that the China National Medical Products Administration (NMPA) has approved XPOVIO ® (selinexor) in combination with bortezomib and dexamethasone (XVd) for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy, a new indication of XPOVIO ®. This approval for XPOVIO ® is based on the data of the BENCH trial, a randomized, controlled, open-label, multicenter Phase III bridging study which compared the safety and efficacy of XVd and Vd regimens in 154 Chinese patients with R/R MM who have received one to three prior lines of therapy. The efficacy and safety data of the BENCH study are generally consistent with those from the global, multicenter, Phase III BOSTON study and met the objectives of the bridging study which showed: Clear superiority of the XVd regimen: compared to the Vd regimen, the XVd regimen demonstrated better clinical efficacy, longer PFS and DOR, a higher ORR, a higher rate of very good partial response (VGPR) or deeper responses and minimal residual disease (MRD) negativity, as well as a trend of prolonged OS. Notable clinical benefits for elderly patients: the study observed particularly notable efficacy in the cohort of elderly patients aged ≥65, validating XPOVIO ® as a better treatment option for this patient population. Prof. Jin Lu, principal investigator of the BENCH study from Peking University People ' s Hospital, said, "MM is the second most common hematologic malignancy. The clinical application of autologous hematopoietic stem cell transplantation (ASCT) and novel agents in the first-line setting have resulted in longer overall survival for patients. However, the condition remains incurable with most patients end up relapsing. As a novel inhibitor of the nuclear export protein that adopts a novel mechanism of action, selinexor was proven by the BENCH study to be significantly efficacious in Chinese patients with MM. This approval for XPOVIO ® is a great news for patients with R/R MM, especially those relapsing for the first time." Prof. Jian Hou, principal investigator of the BENCH study from Shanghai Jiaotong University School of Medicine Affiliated Renji Hospital, commented, "The incidence of MM has been steadily rising year after year. According to the Globocan statistics for 2022, there were 30,300 new cases of MM and 18,662 MM related deaths in China, a figure that highlights an urgent unmet clinical need. Selinexor in combination with bortezomib and dexamethasone incorporates a unique mechanism of action and demonstrated significant efficacy. Moreover, XPOVIO ® does not require intravenous administration, therefore provides clinicians a new treatment strategy that can effectively reduce burden on patients." With a novel mechanism of action, XPOVIO ® is the world's first approved orally-available, selective XPO1 inhibitor, which has already been approved in ten countries and regions in APAC, and has been included in the national insurance schemes in five of these markets (the mainland of China, Taiwan market, Australia, Singapore and South Korea). While bringing XPOVIO ® to more APAC markets, Antengene is also striving to expand the indications of XPOVIO ®. Leveraging the drug's novel mechanism of action, Antengene is currently developing multiple combination regimens of XPOVIO ® for the treatment of various indications including myelofibrosis (MF) and endometrial cancer. About Antengene Antengene Corporation Limited ("Antengene", SEHK: is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders". Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 31 investigational new drug (IND) approvals in the U.S. and Asia, and submitted new drug applications (NDAs) in 11 Asia Pacific markets, with the NDA for XPOVIO ® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia. Forward-looking statements The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2024, and the documents subsequently submitted to the Hong Kong Stock Exchange. For more information, please contact:
